Nephros (NEPH) Projected to Release Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Nephros to post earnings of $0.01 per share and revenue of $4.9940 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last issued its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. Nephros had a return on equity of 7.66% and a net margin of 4.06%.The company had revenue of $5.21 million for the quarter, compared to analyst estimates of $5.02 million. On average, analysts expect Nephros to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Nephros Price Performance

NEPH opened at $3.24 on Thursday. The company has a market capitalization of $35.19 million, a PE ratio of 46.29 and a beta of 1.49. Nephros has a fifty-two week low of $2.66 and a fifty-two week high of $6.42. The business has a 50-day moving average of $3.48 and a 200-day moving average of $3.56.

Wall Street Analyst Weigh In

A number of research firms recently commented on NEPH. Zacks Research upgraded Nephros to a “hold” rating in a report on Monday, July 20th. Weiss Ratings downgraded shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, July 17th. Finally, Northland Securities began coverage on shares of Nephros in a research report on Friday, July 17th. They issued a “market perform” rating and a $4.00 target price for the company. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in Nephros by 3.2% during the second quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock valued at $381,000 after purchasing an additional 2,898 shares during the last quarter. Topline Capital Management LLC boosted its holdings in shares of Nephros by 13.1% during the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after buying an additional 55,360 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Nephros during the 3rd quarter worth $64,000. Citadel Advisors LLC grew its stake in Nephros by 39.2% in the 3rd quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in Nephros by 7.2% in the 4th quarter. HighTower Advisors LLC now owns 59,710 shares of the company’s stock valued at $291,000 after buying an additional 4,000 shares during the last quarter. 41.10% of the stock is owned by institutional investors.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.